Compare AbbVie Inc (ABBV) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs VanEck Vietnam ETF — how do they compare? AbbVie Inc trades at $248.5 (market cap $441.94B), while VanEck Vietnam ETF trades at $17.65. The key difference: AbbVie Inc pays a 2.77% dividend while VanEck Vietnam ETF pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | VNM | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $19.80 |
52-Week Low | $197.38 | $16.34 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
VNM trades at $17.44, showing minimal daily change. Technical indicators are bullish overall, with moving averages signaling strength, while oscillators remain neutral. Key support and resistance levels are tightly clustered around $17 and $18. Recent news highlights regional capital flows and Vietnam-specific challenges, including power grid strain and FTSE Russell's emerging market reclassification affecting the ETF's performance.
The outlook is mixed, with technical strength countered by fundamental data gaps and external risks. Investment opportunity hinges on Vietnam's economic trajectory and foreign investment inflows, but risks include macroeconomic pressures and domestic infrastructure issues. Clarity on financial metrics is essential for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
